EcoDrugPlus

Carbonic Anhydrase 14

Ensembl ID : ENSPPYG00000000906
Gene Symbol: CA14
5 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 2

Ensembl ID : ENSPPYG00000018718
Gene Symbol: CA2
4 Cross references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 3

Ensembl ID : ENSPPYG00000018717
Gene Symbol: CA3
5 Cross references
307 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 4

Ensembl ID : ENSPPYG00000036446
Gene Symbol: CA4
5 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 5a

Ensembl ID : ENSPPYG00000007634
Gene Symbol: CA5A
5 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 5b

Ensembl ID : ENSPPYG00000020149
Gene Symbol: CA5B
5 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 6

Ensembl ID : ENSPPYG00000001919
Gene Symbol: CA6
5 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 7

Ensembl ID : ENSPPYG00000007429
Gene Symbol: CA7
5 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 9

Ensembl ID : ENSPPYG00000019090
Gene Symbol: CA9
5 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Casein Kinase 2 Alpha 1

Ensembl ID : ENSPPYG00000010866
Gene Symbol: CSNK2A1
4 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Casein Kinase I

Ensembl ID : ENSPPYG00000011818
Gene Symbol: LOC100447547
4 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Caspase 1

Ensembl ID : ENSPPYG00000003826
Gene Symbol: CASP1
4 Cross references
420 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).